Company intelligence / Profile preview

Tem Innovations

München, Bayern, Germanydnb.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s flagship product, the ROTEM system, is a fully automated viscoelastic hemostasis analyzer used to assess blood clotting in real time. It has been evaluated in multiple clinical trials: “Predictive Value of ROTEM Analysis and Standard Coagulation Tests in Hospitalized Patients with COVID‑19” – completed study. “ROTEM Sigma Performance Evaluation – Method Comparison With Predicate Device and Reference Intervals” – method comparison study. These studies support its use for rapid assessment of coagulation status in critical care settings.

Therapeutic areas: Hematology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Hospitals/clinical research centers using their devices for trials

Beyond the preview

Go deeper on Tem Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tem Innovations.

Explore the full profile